A Phase 2 Study of Oral MKC-1 Administered Twice Daily for 14 Consecutive Days Every 4 Weeks in Patients With Advanced or Metastatic Breast Cancer.
Phase of Trial: Phase II
Latest Information Update: 02 Oct 2014
At a glance
- Drugs MKC 1 (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors CASI Pharmaceuticals
- 09 Jun 2009 Actual end date (Nov 2008) added as reported by ClinicalTrials.gov.
- 24 Nov 2008 Status changed from active, no longer recruiting to completed.
- 02 Jul 2008 Status changed from recruiting to in progress as stated on the EntreMed website.